A Phase I/II, Open Label Study to Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Docetaxel Monotherapy in Patients With Advanced/Metastatic Triple Negative Breast Cancer (TNBC).

Trial Profile

A Phase I/II, Open Label Study to Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Docetaxel Monotherapy in Patients With Advanced/Metastatic Triple Negative Breast Cancer (TNBC).

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Aug 2016

At a glance

  • Drugs BLEX 404 (Primary) ; Docetaxel
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors BioLite Inc
  • Most Recent Events

    • 11 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top